Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signaling satiety (3, 4), and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction (5, 6).”
BackgroundSelf-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Cited by
Items 101–200 of 599
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01106-4 · Cited by 55
Twarog, C., McCartney, F., Harrison, S. M., Illel, B., Fattal, E., & Brayden, D. J. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105685 · Cited by 55
Abramson, A., Halperin, F., Kim, J., & Traverso, G. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.04.022 · Cited by 54
Bashir, S., Fitaihi, R. A., & Abdelhakim, H. E. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106374 · Cited by 53
Pinto, S., Hosseini, M., Buckley, S. T., Yin, W., Garousi, J., Gräslund, T., van IJzendoorn, S., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.015 · Cited by 53
Self-citationGastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC ‐ What is Coming Next?
Bohley, M., & Leroux, J. (2024) · Advanced Science · doi:10.1002/advs.202400843 · Cited by 53
Novel formulations and drug delivery systems to administer biological solids
Zhang, Y., Davis, D. A., AboulFotouh, K., Wang, J., Williams, D., Bhambhani, A., Zakrewsky, M., Maniruzzaman, M., Cui, Z., & Williams, R. O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.011 · Cited by 52
Ganesh, A. N., Heusser, C., Garad, S., & Sánchez-Félix, M. V. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100079 · Cited by 50
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Li, A., Su, X., Hu, S., & Wang, Y. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110605 · Cited by 49
Szunerits, S., Melinte, S., Barras, A., Pagneux, Q., Voronova, A., Abderrahmani, A., & Boukherroub, R. (2021) · Chemical Society Reviews · doi:10.1039/c9cs00886a · Cited by 49
Bækdal, T. A., Breitschaft, A., Donsmark, M., Maarbjerg, S. J., Søndergaard, F. L., & Borregaard, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01078-y · Cited by 48
Self-citationWright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Self-citationOral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives
Ding, B., Zhu, Z., Guo, C., Li, J., Gan, Y., & Yu, M. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.019 · Cited by 46
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 47
Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations
Dahlgren, D., Sjöblom, M., & Lennernäs, H. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.07.013 · Cited by 46
Bækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M., Søndergaard, F. L., & Connor, A. L. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.938 · Cited by 45
Self-citationKim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 45
Tran, H., Aihara, E., Mohammed, F. A., Qu, H., Riley, A., Su, Y., Lai, X., Huang, S., Aburub, A., Chen, J. J. H., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00443 · Cited by 44
Microcontainers for oral insulin delivery – In vitro studies of permeation enhancement
Jørgensen, J. R., Jepsen, M. L., Nielsen, L. H., Dufva, M., Nielsen, H. M., Rades, T., Boisen, A., & Müllertz, A. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.08.011 · Cited by 44
Gleeson, J. P., Fein, K. C., Chaudhary, N., Doerfler, R., Newby, A. N., & Whitehead, K. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120120 · Cited by 44
Synthetic antimicrobial peptides control Penicillium digitatum infection in orange fruits
Lima, P. G., Freitas, C. D. T., Oliveira, J. T. A., Neto, N. A. S., Amaral, J. L., Silva, A. F. B., de Sousa, J. S., Franco, O. L., & Souza, P. F. N. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110582 · Cited by 44
Development and Regulatory Challenges for Peptide Therapeutics
Zane, D., Feldman, P. L., Sawyer, T. K., Sobol, Z., & Hawes, J. J. (2020) · International Journal of Toxicology · doi:10.1177/1091581820977846 · Cited by 43
A Review on the Efficacy and Safety of Oral Semaglutide
Niman, S., Hardy, J., Goldfaden, R. F., Reid, J., Sheikh‐Ali, M., SUTTON, D. R., & Choksi, R. R. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00341-8 · Cited by 43
Oral delivery of peptide therapeutics in infants: Challenges and opportunities
Gleeson, J. P., Fein, K. C., & Whitehead, K. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.011 · Cited by 43
Transmucosal Absorption Enhancers in the Drug Delivery Field
Maher, S., Casettari, L., & Illum, L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070339 · Cited by 43
SNAC for Enhanced Oral Bioavailability: An Updated Review
Kommineni, N., Jyothi, V. G. S. S., Butreddy, A., Saka, R., Shapira, T., Khan, W., Angsantikul, P., & Domb, A. J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03459-9 · Cited by 42
Oral Delivery of Biologics via the Intestine
New, R. R. C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010018 · Cited by 42
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk
Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J. E., & Krutsch, K. (2024) · Nutrients · doi:10.3390/nu16172886 · Cited by 41
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 42
Hauge, C., Breitschaft, A., Hartoft‐Nielsen, M., Jensen, S., & Bækdal, T. A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1955856 · Cited by 42
Self-citationOral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 42
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 40
Smart pills and drug delivery devices enabling next generation oral dosage forms
Milián-Guimerá, C., McCabe, R., Thamdrup, L. H. E., Ghavami, M., & Boisen, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.041 · Cited by 40
Yang, X., Li, W., Li, S., Chen, S., Hu, Z., He, Z., Zhu, X., Niu, X., Zhou, X., Li, H., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.042 · Cited by 40
Design of a self-unfolding delivery concept for oral administration of macromolecules
Jørgensen, J. R., Thamdrup, L. H. E., Kamguyan, K., Nielsen, L. H., Nielsen, H. M., Boisen, A., Rades, T., & Müllertz, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.024 · Cited by 39
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01554-1 · Cited by 38
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
Pearson, S. M., Kietsiriroje, N., & Ajjan, R. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s229802 · Cited by 38
Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size
Fein, K. C., Gleeson, J. P., Newby, A. N., & Whitehead, K. A. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.11.010 · Cited by 38
Wang, M., Amakye, W. K., Gong, C., Ren, Z., Yuan, E., & Ren, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.003 · Cited by 38
Ionic Liquids: Promising Approach for Oral Drug Delivery
Jiang, L., Sun, Y., Lu, A., Wang, X., & Shi, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03260-8 · Cited by 38
Oral delivery of glutathione: antioxidant function, barriers and strategies
Wei, T., Thakur, S. S., Liu, M., & Wen, J. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0005 · Cited by 38
Grancieri, M., Verediano, T. A., Sant'Ana, C. T., de Assis, A., Toledo, R. L., de Mejia, E. G., & Martino, H. S. D. (2022) · PharmaNutrition · doi:10.1016/j.phanu.2022.100298 · Cited by 37
Alhindi, Y., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 37
Progress and limitations of oral peptide delivery as a potentially transformative therapy
Tran, H., & ElSayed, M. E. H. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2051476 · Cited by 37
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Ono, R., Furihata, K., Ichikawa, Y., Nakazuru, Y., Bergman, A., Gorman, D. N., & Saxena, A. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14928 · Cited by 36
Hansen, B. B., Nuhoho, S., Ali, S. N., Dang-Tan, T., Valentine, W. J., Malkin, S. J. P., & Hunt, B. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1722678 · Cited by 36
Qian, P., Tian, H., Wang, Y., Lu, W., Li, Y., Ma, T., Gao, X., & Yao, W. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114209 · Cited by 36
Gleeson, J. P., Zhang, S. Y., Subelzú, N., Ling, J., Nissley, B. P., Ong, W. S. Y., Nofsinger, R., & Kesisoglou, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00210 · Cited by 35
Page, S., Khan, T. A., Kühl, P. G., Schwach, G., Storch, K., & Chokshi, H. P. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-093517 · Cited by 35
Pentafragka, C., Vertzoni, M., Dressman, J., Symillides, M., Goumas, K., & Reppas, C. I. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105535 · Cited by 35
Hristov, D. R., McCartney, F., Beirne, J., Mahon, E., Reid, S., Bhattacharjee, S., Pénarier, G., Ulrich, W., Bazile, D., & Brayden, D. J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b16104 · Cited by 34
Kneiszl, R., Hossain, S., & Larsson, P. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00689 · Cited by 34
Challenges in Permeability Assessment for Oral Drug Product Development
Koziolek, M., Augustijns, P., Berger, C., Cristofoletti, R., Dahlgren, D., Keemink, J., Matsson, P., McCartney, F., Metzger, M., Mezler, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102397 · Cited by 34
Gelli, H. P., Vazquez-Uribe, R., Buckley, S. T., Andersen, J. T., & Sommer, M. O. A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115603 · Cited by 33
Self-citationWILSON, C. G., Aarons, L. J., Augustijns, P., Brouwers, J., Darwich, A. S., de Waal, T., Garbacz, G., Hansmann, S., Hoc, D., Ivanova, A., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106100 · Cited by 33
Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier
Werner, J., Umstätter, F., Hertlein, T., Mühlberg, E., Beijer, B., Wohlfart, S., Zimmermann, S., Haberkorn, U., Ohlsen, K., Fricker, G., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303654 · Cited by 33
Devices to overcome the buccal mucosal barrier to administer therapeutic peptides
Malhotra, S., Lijnse, T. M., O’Cearbhaill, E. D., & Brayden, D. J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115572 · Cited by 33
Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity
Hira, T., Trakooncharoenvit, A., Taguchi, H., & Hara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126623 · Cited by 32
Revealing the importance of carrier-cargo association in delivery of insulin and lipidated insulin
Diedrichsen, R. G., Rønholt, S., Ulrich, W., Besenius, M., Leberer, E., Kristensen, M., & Nielsen, H. M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.030 · Cited by 32
Tran, H., Dogra, M., Huang, S., Aihara, E., ElSayed, M. E. H., & Aburub, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123680 · Cited by 31
Dahlgren, D., Olander, T., Sjöblom, M., Hedeland, M., & Lennernäs, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.019 · Cited by 31
Strategies to Optimize Peptide Stability and Prolong Half-Life
Shi, S. M., & Di, L. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-04544-8_4 · Cited by 31
The future of the GLP-1 receptor agonists
Hirsch, I. B. (2019) · JAMA · doi:10.1001/jama.2019.2941 · Cited by 30
Novel enabling strategies for oral peptide delivery
Öngoren, B., Kara, A., Serrano, D. R., & Lalatsa, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125888 · Cited by 30
In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin
Jørgensen, J. R., Yu, F., Venkatasubramanian, R., Nielsen, L. H., Nielsen, H. M., Boisen, A., Rades, T., & Müllertz, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010048 · Cited by 30
Binding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
Self-citationChen, H., Sun, J., Fang, H., Lin, Y., Wu, H., Lin, D., Yang, Z., Zhou, Q., Zhao, B., Zhou, T., et al. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2400106 · Cited by 29
Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs
Colston, K. J., Faivre, K. T., & Schneebeli, S. T. (2025) · Nature Communications · doi:10.1038/s41467-025-64891-0 · Cited by 29
Berg, S., Edlund, H., Goundry, W. R. F., Bergström, C. A. S., & Davies, N. M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122238 · Cited by 29
Aptamer-modified M cell targeting liposomes for oral delivery of macromolecules
He, Y., Huang, Y., Xu, H., Yang, X., Liu, N., Xu, Y., Ma, R., Zhai, J., Ma, Y., & Guan, S. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113109 · Cited by 29
Yamada, H., Yoshida, M., Funazaki, S., Morimoto, J., Tonezawa, S., Takahashi, A., Nagashima, S., Masahiko, K., Kiyoshi, O., & Hara, K. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040176 · Cited by 29
Candido, R., Gaiotti, S., Giudici, F., Toffoli, B., Luca, F. D., Velardi, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186052 · Cited by 29
Advances in biosynthesis of peptide drugs: Technology and industrialization
Wang, J., Chen, L., Qin, S., Xie, M., Luo, S., & Li, W. (2023) · Biotechnology Journal · doi:10.1002/biot.202300256 · Cited by 28
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Ke, Z., Ma, Q., Ye, X., Wang, Y., Jin, Y., Zhao, X., & Su, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116471 · Cited by 28
Vazquez-Uribe, R., Hedin, K. A., Licht, T. R., Nieuwdorp, M., & Sommer, M. O. A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.021 · Cited by 28
Horii, T., Masudo, C., Takayanagi, Y., Oikawa, Y., Shimada, A., & Mihara, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14265 · Cited by 28
Hunt, B., Hansen, B. B., Ericsson, Å., Kallenbach, K., Ali, S. N., Dang‐Tan, T., Malkin, S. J. P., & Valentine, W. J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01125-y · Cited by 28
Effect of excipients on oral absorption process according to the different gastrointestinal segments
Ruiz-Picazo, A., Lozoya-Agulló, I., González‐Álvarez, I., Bermejo, M., & González‐Álvarez, M. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1813108 · Cited by 28
Fadini, G. P., Bonora, B. M., Ghiani, M., Anichini, R., Melchionda, E., Fattor, B., Fazion, S., Meregalli, G., Giaccari, A., Avogaro, A., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15554 · Cited by 27
Jordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand-Øregaard, A., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 27
Self-citationPratley, R. E., Crowley, M. J., Gislum, M., HERTZ, C. L., Jensen, T. B., Khunti, K., Mosenzon, O., & Buse, J. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00994-9 · Cited by 27
Imaging therapeutic peptide transport across intestinal barriers
Larsen, J. B., Taebnia, N., Dolatshahi‐Pirouz, A., Eriksen, A. Z., Hjørringgaard, C. U., Kristensen, K., Larsen, N. W., Larsen, N. B., Marie, R., Mündler, A.-K., et al. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00024a · Cited by 28
Tyagi, P., Trivedi, R., Pechenov, S., Patel, C., Revell, J. D., Wills, S., Huang, Y., Rosenbaum, A. I., & Subramony, J. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.002 · Cited by 27
Twarog, C., Fattal, E., Noiray, M., Illel, B., Brayden, D. J., Taverna, M., & Hillaireau, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122131 · Cited by 27
Bao, X., Qian, K., Xu, M., Chen, Y., Wang, H., Pan, T. S., Wang, Z., Yao, P., & Lin, L. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01743-9 · Cited by 27
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
Dahlgren, D., Sjöblom, M., Hedeland, M., & Lennernäs, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020099 · Cited by 27
Xiong, S., Gou, R., Liang, X., Wu, H., Qin, S., Li, B., Luo, C., & Chen, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01594-7 · Cited by 26
Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
Wang, X., Wang, K., Fang, Y., Zhang, Y., Yi, L., Li, X., Zhao, Q., Zhu, X., Cai, S., & Wan, L. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102763 · Cited by 25
van Hout, M., Forte, P., Jensen, T. B., Boschini, C., & Bækdal, T. A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01223-9 · Cited by 25
Self-citationSmits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 26
Piperine: A possible permeation enhancer for oral protein delivery
Raghunath, I., Koland, M., & Narayanan, A. V. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.157160 · Cited by 25
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.